# Revelyx Bio

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/revelyx-bio

- Headquarters: Delaware, US
- Latest round: Series A (Jan 9, 2026)
- Investors on record: 1

## About

Founded in 2025 and based in Ohio, US, Revelyx Bio Inc. operates as a biotech company developing liquid botulinum toxin products for cosmetic and medical use. In January 2026, Revelyx Bio Inc. raised series A funding led by NRL Capital.

Revelyx Bio specializing in next-generation botulinum toxin therapies designed for aesthetic and medical applications. The firm develops botulinum toxin type A liquid formulation (pipeline: 003) engineered for higher efficacy, lower immunogenicity, improved resistance profiles, and greater precision, offering a more user-friendly alternative to traditional toxin products.

The company plans to use the series A funding to promote clinical research and development and expand its products globally.

## Funding rounds

- Series A, Jan 9, 2026 — NRL Capital

## Investors

- NRL Capital (https://capitalatlas.ai/funds/nrl-capital) — Series A